surmount-1 trial tirzepatide weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled 💊 Could a new medication

Magnesium deficiency has been associated with muscle pain, fatigue, difficulty sleeping, and anxietycommon symptoms of FM

My cycle is mostly 28 days

Read on to find out if your Blue Cross Blue Shield insurance covers bariatric surgery

It sets the boundaries for how the material is purchased, stored, described, and used inside the lab

They are a sign that your body is adapting to a new metabolic reality, and it needs some support during the transition

Findings: RCTSURMOUNT-MAINTAIN - Tirzepatide for Maintenance of Bodyweight Reduction in Obesity, Lancet (2026) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=378 | length = 112 weeks) in adults with obesity who completed 60 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg once weekly) Treatment: Continue tirzepatide maximum tolerated dose (MTD